Copyright
©The Author(s) 2021.
World J Clin Cases. Apr 16, 2021; 9(11): 2419-2432
Published online Apr 16, 2021. doi: 10.12998/wjcc.v9.i11.2419
Published online Apr 16, 2021. doi: 10.12998/wjcc.v9.i11.2419
Ref. | Country | Number of patients | Proportion of cirrhosis | Causes and their proportion of liver cirrhosis | Diagnostic method of PHT | Proportion of PHT | 1-yr overall survival | 3-yr overall survival | 5-yr overall survival | Statistical significance |
Di Sandro et al[42], 2018 | Italy | LLR/OLR, 75/75 | All | Virus/Alcohol/Virus + Alcohol/Other, 92/24/16/18 | Non-invasive tests | PartialLLR ≈ OLR | LLR/OLR, 98%/90% | LLR/OLR, 76%/ 68% | LLR/OLR, 60%/58% | NSD |
Le Roux et al[67], 2017 | France | LLR/OLR, 38/24 | All | Virus/Alcohol/NASH/Other, 6/29/21/6 | Non-invasive tests | PartialLLR ≈ OLR | NA | NA | NA | NA |
El-Gendi et al[60], 2017 | Egypt | LLR/OLR, 25/25 | All | Virus, 50 | Non-invasive tests | PartialLLR ≈ OLR | NA | NA | NA | NA |
Tarantino et al[40], 2017 | Italy | LLR/OLR, 13/51 | All | Virus/Alcohol/NASH/Other, 59/1/2/2 | HVPG + Non-invasive tests | PartialLLR ≈ OLR | NA | NA | NA | NA |
Sposito et al[61], 2016 | Italy | LLR/OLR, 43/43 | All | Virus/Other, 67/19 | Non-invasive tests | Partial | LLR/OLR, 98%/88% | LLR/OLR, 75%/79% | LLR/OLR, 38%/46% | NSD |
Harada et al[43], 2016 | Japan | LLR/OLR, 20/48 | All | Virus/Other, 58/10 | Non-invasive tests | All | LLR/OLR, 100%/98% | LLR/OLR, 90%/68% | LLR/OLR, 90%/54% | NSD |
Memeo et al[48], 2014 | France | LLR/OLR, 45/45 | All | Virus/Alcohol, 64/26 | Non-invasive tests | PartialLLR ≈ OLR | LLR/OLR, 88%/63% | LLR/OLR, 59%/44% | LLR/OLR, 12%/22% | NSD |
Truant et al[39], 2011 | France | LLR/OLR, 36/53 | All | Virus/Alcohol/Other, 17/55/17 | HVPG + Non-invasive tests | PartialLLR ≈ OLR | LLR/OLR, 98%/85% | LLR/OLR, 80%/64% | LLR/OLR, 70%/46% | NSD |
Belli et al[44], 2009 | Italy | LLR/OLR, 54/125 | All | Virus/Other, 175/4 | Non-invasive tests | PartialLLR ≈ OLR | LLR/OLR, 94%/94% | LLR/OLR, 67%/62% | NA | NSD |
Berger et al[68], 2018 | America | LRFA/ORFA, 478/177 | All | NA | Non-invasive tests | All | NA | NA | NA | NA |
Casaccia et al[50], 2017 | Italy | LLR/LRFA, 22/24 | All | Virus/Alcohol/Virus + Alcohol/Other, 33/9/1/2 | Non-invasive tests | Partial | LLR/LRFA, 96%/88% | LLR/LRFA, 84%/54% | LLR/LRFA, 70%/32% | SD |
Santambrogio et al[69], 2015 | Italy | (LLR+OLR)/LRFA, 76/76 | All | Virus/Other, 122/30 | Non-invasive tests | Partial | (LLR + OLR)/LRFA, 94%/88% | (LLR + OLR)/LRFA, 82%/62% | (LLR + OLR)/LRFA, 69%/48% | SD |
Ref. | Number of patients | Minor hepatectomy, < 3 adjacent segments | Major hepatectomy, ≥ 3 adjacent segments | Conversion laparotomy rate | Operative blood loss | Transfusion requirements | Margins, cm | R0 resection rate | Operative time | Length of stay | Complications |
Di Sandro et al[42], 2018 | LLR/OLR, 75/75 | LLR/OLR, 74/73 | LLR/OLR, 1/2 | 0 (0) | LLR < OLR | Equivalent | LLR > OLR | Equivalent | Equivalent | LLR < OLR | LLR < OLR |
Le Roux et al[67], 2017 | LLR/OLR, 38/24 | LLR/OLR, 25/23 | LLR/OLR, 13/1 | NA | Equivalent | NA | NA | NA | NA | LLR < OLR | LLR < OLR |
El-Gendi et al[60], 2017 | LLR/OLR, 25/25 | NA | NA | 0 (0) | Equivalent | Equivalent | Equivalent | Equivalent | Equivalent | LLR < OLR | Equivalent |
Tarantino et al[40], 2017 | LLR/OLR, 13/51 | LLR/OLR, 13/51 | NO | 3 (23.1%) | Equivalent | NA | NA | Equivalent | Equivalent | LLR < OLR | LLR < OLR |
Sposito et al[61], 2016 | LLR/OLR, 43/43 | LLR/OLR, 42/41 | LLR/OLR, 1/2 | 2 (4.7%) | Equivalent | NA | Equivalent | Equivalent | Equivalent | LLR < OLR | LLR < OLR |
Harada et al[43], 2016 | LLR/OLR, 20/48 | LLR/OLR, 20/45 | LLR/OLR, 0/3 | NA | LLR < OLR | Equivalent | NA | NA | LLR < OLR | NA | Equivalent |
Memeo et al[48], 2014 | LLR/OLR, 45/45 | LLR/OLR, 43/43 | LLR/OLR, 2/2 | NA | Equivalent | Equivalent | NA | NA | LLR < OLR | LLR < OLR | LLR < OLR |
Truant et al[39], 2011 | LLR/OLR, 36/53 | LLR/OLR, 36/53 | NO | 7 (19.4%) | Equivalent | Equivalent | Equivalent | NA | Equivalent | LLR < OLR | Equivalent |
Belli et al[44], 2009 | LLR/OLR, 54/125 | LLR/OLR, 51/86 | LLR/OLR, 3/39 | 4 (7.4%) | LLR < OLR | LLR < OLR | LLR > OLR | LLR > OLR | LLR < OLR | Equivalent | LLR < OLR |
Berger et al[68], 2018 | LRFA/ORFA, 478/177 | NA | NA | NA | NA | NA | NA | NA | LRFA < ORFA | LRFA < ORFA | LRFA < ORFA |
Casaccia et al[50], 2017 | LLR/LRFA, 22/24 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Santambrogio et al[69], 2015 | (LLR+OLR)/LRFA, 76/76 | NA | NA | 8 (27.6%) | NA | NA | NA | NA | NA | NA | NA |
- Citation: Shen ZF, Liang X. Current status of radical laparoscopy for treating hepatocellular carcinoma with portal hypertension. World J Clin Cases 2021; 9(11): 2419-2432
- URL: https://www.wjgnet.com/2307-8960/full/v9/i11/2419.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i11.2419